Patients in the EU with giant cell arteritis (GCA), an inflammation of the arteries, could soon have the first oral targeted treatment for the disease after AbbVie's Rinvoq was recommended for ...

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes inflammation of the large arteries.

RINVOQ is the first and only oral Janus kinase (JAK) inhibitor approved in the European Union (EU) to treat adult patients with giant cell arteritis (GCA) The approval is supported by data from ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an ...

Rinvoq is a Key Top-Line Driver for AbbVie Rinvoq is a key top-line driver for AbbVie. The drug generated sales of almost $6 billion in 2024, which was up 50.4% year over year, owing to continuous ...

AbbVie expects sales for Rinvoq and Skyrizi together to reach $31 billion as soon as 2027. Both pharmaceutical stocks yield over 3% and could be a solid addition to investors' portfolios.

AbbVie ABBV announced that the European Commission has granted marketing approval to its blockbuster drug Rinvoq for treating giant cell arteritis (“GCA”), an autoimmune disease that causes ...

AbbVie has won expanded European approval of its blockbuster autoimmune drug Rinvoq for the treatment of adults with giant cell arteritis. AbbVie on Tuesday said the European Commission's nod ...